Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer.

Introduction: Radium-223 dichloride (Ra-223) is recommended as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) patients with symptomatic bone metastases and no visceral disease, after docetaxel failure, or in patients who are not candidates to receive it. In this study, we aimed to ambispectively analyze overall survival (OS) and prognostic features in mCRPC in patients receiving Ra-223 as per clinical routine practice and identify the most suitable treatment sequence. Patients and methods: This study is observational, multicentric, and ambispective. Eligibility criteria included mCRPC patients treated with Ra-223, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, without visceral metastases, and no more than three cm involved lymph nodes. Results: A total of 145 patients were included; the median age was 73.97 years, and a Gleason score of more than or equal to 7 in 61 (48%) patients; 73 (81%) had previously received docetaxel. The most important benefit was reached by those patients who received Ra-223 in the second-line setting, with a median OS of 17 months (95% CI, 12-21), and by patients who received six cycles of treatment, with a median OS of 19 months (95% CI, 14-21). An alkaline phosphatase (ALP) decrease was also identified as a prognosis marker. When performing the multivariate analysis, the time to develop castration-resistant disease longer than 24 months was the most important prognostic factor to predict the evolution of the patients receiving Ra-223. Ra-223 was well tolerated, with thrombocytopenia, anemia, and diarrhea being the main adverse events. Conclusion: There is a benefit for those patients who received Ra-223 in the second-line setting, regardless of prior use of docetaxel. In addition, a survival benefit for patients presenting with a decline in ALP was observed.

Percutaneous nephrolithotomy: short- and long-term effects on health-related quality of life.

BACKGROUND AND PURPOSE: Percutaneous nephrolithotomy (PCNL) is the treatment of choice for large and complex kidney stones, having increased its safety and effectiveness over the last years. Nonetheless, there is little known about its impact on quality of life (QoL). This study aimed at evaluating the effects of PCNL on patients' QoL in the short and long term. PATIENTS AND METHODS: We prospectively studied 40 consecutive cases who underwent PCNL. QoL was measured using the short form-36 (SF-36) questionnaire, 2 weeks before surgery and then in the third postoperative month and a year after. Changes in QoL were assessed under statistical and clinical relevance criteria. RESULTS: PCNL has rendered 70% of the cases completely stone free with a 35% complication rate (33% Clavien I+II). The baseline scores of all SF-36 domains were worse than the referral population. Three months after PCNL, bodily pain was the only dimension whose change was relevant for patients (effect size [ES]=0.71, minimal clinically important difference [MCID]=0.56). A year after, this favorable effect of PCNL on body pain is still present, being also beneficial on both role physical (ES=0.58, MCID=0.52) and the physical component summary (ES=0.56, MCID=0.43). Social function was also close to reaching clinical relevance a year after the procedure (ES=0.66, MCID=0.72). CONCLUSION: Kidney stone disease considerably affects the patients' QoL. PCNL not only has good outcomes rendering the kidney stone free without major complications but produces an immediate body pain relief. This is perceived as relevant by the patients even a year after the procedure, when some other physical aspects of QoL also get better, helping patients to restore their social activities.

Adenomatoid paratesticular tumor: report of 5 new cases and literature review.

OBJECTIVE: To report 5 cases of adenomatoid tumor of the epididymis that have been diagnosed in the last 11 years at our hospital. We performed a bibliographic review with discussion of diagnosis, differential diagnosis and treatment of this rare type of lesion. METHOD: We have performed a retrospective analysis of epididymal adenomatoid tumors diagnosed during the last 11 years in our hospital, from January 2001 to June 2012. RESULTS: The average age of the series was 44 years. The predominant reason for consultation was long duration painless scrotal mass, with palpable nodule, usually dependent of the epididymis. 60% of the patients have been studied with abdominal ultrasound, which showed a nodular paratesticular lesion, with an echogenicity compatible with solid tissue. Tumor markers associated with testicular tumors (alpha-fetoprotein (AFP)), beta-human chorionic gonadotropin (b-HCG) and lactate dehydrogenase (LDH) were analyzed in 60% of the cases, being normal in all patients. 3 lumpectomies, 1 epididymectomy and 1 radical orchiectomy have been performed. CONCLUSIONS: The discovery of a solid epididymal mass is uncommon in clinical practice. Physical examination and imaging tests should confirm the paratesticular origin of the lesion, being then trans-scrotal epididymectomy the treatment of choice. If diagnosis is uncertain, inguinal approach and intraoperative biopsy are mandatory.